The leaflets of the Ministry of Health on the correct use of drugs in the treatment of Covid-19 have been sent to all provinces – Health News



[ad_1]

Ministry of HealthDeadly global epidemic new type of corona virus (COVID-19The brochures prepared for the correct use of medication in the treatment of) were sent with 81.

According to the written statement made by the Ministry, the issue of “mixing the dose of the drug” was clarified in the brochures prepared in accordance with the diagnosis and treatment guide of the Coronavirus Scientific Committee and sent to all provinces in order to to ensure the effectiveness of the drugs used in the treatment of patients with Covid-19 and to prevent misuse.

In the brochures, both in uncomplicated and possible / definitive outpatient cases of Covid-19 with mild-moderate pneumonia and cases of Covid-19 with indication for hospitalization “Hydroxychloroquine I Favipiravirine“It was recalled that it was recommended that both drugs should be used under the advice and supervision of a physician, and it was emphasized that treatment that started early and continued with drugs taken at the correct dose greatly prevented disease progression and reduced the rate of transition to intensive care.

HOW ARE DRUGS USED?

The brochures explained the usage time and dosages of the drugs, and the unsuitable conditions were noted.

It was noted that favipiravir should be taken 8 in the morning and in the evening on the first day, and then at 3 in the morning and in the evening for 4 days, and that favipiravir is not used in pregnant or lactating mothers .

It is recommended to take 10 hydroxychloroquine tablets, one in the morning and one in the evening, at the end of the fifth day, and it was recalled that this drug is not used in patients with heart disease or arrhythmias.

Brochures were prepared, stating that a doctor should be consulted if side effects are observed or if complaints increase, so that citizens can mark the dose they receive and the follow-up.

CORONA SMART VIRUS MASK

[ad_2]